Cases We report cases of three patients infected with mild coronavirus disease 2019 (COVID‐19) treated only with Kampo medicine and discharged from the hospital without symptom exacerbation. Case 1 A 41‐year‐old healthy female suffering from headache, sore throat, and fever. Case 2: A 16‐year‐old healthy female sufferking from nasal congestion and taste disorder. Case 3: A 12‐year‐old healthy male suffering from nasal congestion and taste disorder. Outcome The three patients were prescribed saikatsugekito. Cases 1 and 3 initially presented with white and yellow tongue coating, which disappeared several days after the prescription of saikatsugekito. All three patients were discharged from the hospital without symptom exacerbation. Conclusion We believe that treatment with Kampo medicine, which is relatively safe clinically and has few side effects, should be taken at an early stage of COVID‐19 along with coping therapy. And we think that saikatsugekito may contribute to prevent the worsening of COVID‐19.
No takes yet. Share an insight, caveat, or question.
Irie et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: